We demonstrated that the MYBL2–CCL2 axis favors a tumor inhibitory effect by promoting the M2-like polarization of recruited macrophages, and that CVT-313 reshapes the tumor microenvironment and reverses resistance to anti-PD-1 therapy. This evidence concerns the gene MYBL2 and neoplasm.